Visualization of the Dopamine Transporter in the Human Brain Postmortem with the New Selective Ligand [125I]PE2I

Using a new, 125I-labeled, selective high affinity dopamine transporter ligand, N-(3-iodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(4'-methy lph enyl)nort ropane (PE2I), the distribution of the dopamine transporter was characterized in the normal postmortem human brain using whole hemisphere autoradiography. PE2I was radioiodinated to high specific radioactivity (2200 Ci/mmol, 81 GBq/micromol). PE2I binds to the dopamine transporter with high potency and, in contrast to beta-CIT, it has very low affinities for the serotonin and noradrenaline transporters. The autoradiograms showed very intense binding in basal ganglia (putamen, nucleus caudatus, nucleus accumbens) and lower binding in substantia nigra. Very low or no binding was found in other brain structures, including the neocortex or cerebellum. The labeling of human dopamine transporters with [125I]PE2I was inhibited by the dopamine transporter inhibitors GBR 12909 and beta-CIT, but not by citalopram (serotonin transporter inhibitor) or maprotiline (noradrenaline transporter inhibitor). Possibly due to the relatively high lipophilicity of the compound (theoretical log p = 4.68), it accumulated slightly in white matter. Thus, in vitro autoradiography using [125I]PE2I provided detailed qualitative and quantitative evidence that the dopamine transporter is almost exclusively localized in the basal ganglia of the human brain. Moreover, the autoradiograms indicate that [11C]PE2I and [123I]PE2I should be suitable for the in vivo visualization of the human dopamine transporter with PET or SPECT, respectively.

[1]  M. Kaufman,et al.  Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35,428) in the monkey brain , 1990, Synapse.

[2]  M. Kuhar,et al.  [123/125I]RTI‐55, an in vivo label for the serotonin transporter , 1992, Synapse.

[3]  C. Halldin,et al.  Synthesis of unlabelled, 3H‐ and 125I‐labelled β‐CIT and its ϖ‐fluoroalkyl analogues β‐CIT‐FE and β‐CIT‐FP, including synthesis of precursors , 1996 .

[4]  G. Sedvall,et al.  Autoradiography with saturation experiments of 11C-Ro 15–1788 binding to human brain sections , 1991, Journal of Neuroscience Methods.

[5]  M Laruelle,et al.  Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [123I]CIT. , 1991, European journal of pharmacology.

[6]  R. Baldessarini,et al.  N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. , 1994, Journal of medicinal chemistry.

[7]  S. Tejani-butt.  [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. , 1992, The Journal of pharmacology and experimental therapeutics.

[8]  M. Caron,et al.  Cloning and functional characterization of a cocaine‐sensitive dopamine transporter , 1991, FEBS letters.

[9]  Christer Halldin,et al.  [11C]β‐CIT‐FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography , 1996 .

[10]  G. Uhl,et al.  Dopamine transporter mRNA: dense expression in ventral midbrain neurons. , 1992, Brain research. Molecular brain research.

[11]  F. Carroll,et al.  Characterization and localization of [125I]RTI-121 binding sites in human striatum and medial temporal lobe. , 1995, The Journal of pharmacology and experimental therapeutics.

[12]  J. Rinne,et al.  Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type , 1994, Brain Research.

[13]  R. Elde,et al.  Dopamine transporter mRNA in neurons of the rat hypothalamus. , 1993, Neuroendocrinology.

[14]  M. Kuhar,et al.  Dopamine transporter immunohistochemistry in median eminence, amygdala, and other areas of the rat brain , 1996, Synapse.

[15]  Raimund Mannhold,et al.  Calculation of Drug Lipophilicity: The Hydrophobic Fragmental Constant Approach , 1992 .

[16]  J. Marcusson,et al.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.

[17]  D. Mash,et al.  Visualizing Dopamine and Serotonin Transporters in the Human Brain with the Potent Cocaine Analogue [125I]RTI‐55: In Vitro Binding and Autoradiographic Characterization , 1994, Journal of neurochemistry.

[18]  D Guilloteau,et al.  Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. , 1997, Journal of medicinal chemistry.

[19]  H. Singer,et al.  Abnormal dopamine uptake sites in postmortem striatum from patients with tourette's syndrome , 1991, Annals of neurology.

[20]  P B Hoffer,et al.  [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. , 1991, Journal of medicinal chemistry.

[21]  A. Graybiel,et al.  Dopamine uptake sites in the striatum are distributed differentially in striosome and matrix compartments. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Y. Hurd,et al.  The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons , 1994, Neuroscience.

[23]  L. Iversen,et al.  Synaptosomes: Different Populations storing Catecholamines and Gamma-aminobutyric Acid in Homogenates of Rat Brain , 1968, Nature.

[24]  M. Bannon,et al.  Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  High-affinity TCRs , 2000, Nature Biotechnology.

[26]  J. Cadet,et al.  Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester. , 1995, Molecular pharmacology.

[27]  J. Seibyl,et al.  Regional brain uptake and pharmacokinetics of [123I]N-ω -fluoroalkyl-2β-carboxy-3β-(4-iodophenyl) nortropane esters in baboons , 1995 .

[28]  C. Tanaka,et al.  [3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics. , 1988, Japanese journal of pharmacology.

[29]  M Laruelle,et al.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Halldin,et al.  Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain , 1994, Synapse.

[31]  C. Halldin,et al.  [O-methyl-11C]beta-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. , 1995, Nuclear medicine and biology.

[32]  Christer Halldin,et al.  Autoradiographic localization of extrastriatal D2‐dopamine receptors in the human brain using [125I]epidepride , 1996, Synapse.

[33]  Christer Halldin,et al.  Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain , 1994, Neuropsychopharmacology.

[34]  G. Sedvall,et al.  PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.

[35]  S. Hersch,et al.  The dopamine transporter: immunochemical characterization and localization in brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[36]  S. Snyder,et al.  Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. , 1969, The Journal of pharmacology and experimental therapeutics.

[37]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[38]  P. Seeman,et al.  Dopamine receptors and transporters in Parkinson's disease and schizophrenia , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  J. Wamsley,et al.  Alterations in the dopaminergic receptor system after chronic administration of cocaine , 1993, Synapse.

[40]  G. Sedvall,et al.  [125I]β-CIT-FE and [125I]β-CIT-FP are superior to [125I]β-CIT for dopamine transporter visualization: Autoradiographic evaluation in the human brain , 1997 .

[41]  J. Kleinman,et al.  Decreased density of human striatal dopamine uptake sites with age. , 1986, European Journal of Pharmacology.